KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Long-Term Investments (2019 - 2025)

Royalty Pharma's Long-Term Investments history spans 7 years, with the latest figure at $290.0 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 55.1% year-over-year to $290.0 million; the TTM value through Dec 2025 reached $290.0 million, up 55.1%, while the annual FY2025 figure was $290.0 million, 55.1% up from the prior year.
  • Long-Term Investments for Q4 2025 was $290.0 million at Royalty Pharma, up from $129.4 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $657.3 million in Q3 2024 and bottomed at $129.4 million in Q3 2025.
  • The 5-year median for Long-Term Investments is $272.9 million (2021), against an average of $290.3 million.
  • The largest annual shift saw Long-Term Investments skyrocketed 355.38% in 2024 before it plummeted 80.31% in 2025.
  • A 5-year view of Long-Term Investments shows it stood at $269.8 million in 2021, then skyrocketed by 47.21% to $397.2 million in 2022, then decreased by 5.36% to $375.9 million in 2023, then plummeted by 50.26% to $187.0 million in 2024, then surged by 55.1% to $290.0 million in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Long-Term Investments are $290.0 million (Q4 2025), $129.4 million (Q3 2025), and $275.9 million (Q2 2025).